SCI Abstract

search
+
Comparative performance of HPV self-sampling and conventional screening methods: A systematic review and bivariate meta-analysis
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Corrigendum to ‘Endometriosis and ovarian cancer risk’ [Gynecologic Oncology 209C (2026) 88–98]
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Opportunistic salpingectomy during non-gynecologic surgery: Canadian surgeons' experience, barriers and facilitators
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Malignant transformation risk and management dilemmas of atypical lobular endocervical glandular hyperplasia: A retrospective cohort study comparing Peutz-Jeghers syndrome versus sporadic cases
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Corrigendum to “Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer” [Volume 208, May 2026, Pages 85–90]
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, includ...
Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer
Advances in the understanding of the molecular biology of endometrial cancer have led to the incorporation of several targ...
Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression
Ovarian cancer (OC) remains the most fatal gynecological malignancy worldwide. Approximately 90 % of OC cases are of epith...
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
ObjectiveCarcinosarcoma (CS) is a rare, aggressive malignancy characterized by high rates of extrauterine spread, frequent...
Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy
Ovarian cancer is a leading cause of cancer-related deaths among women. Although the incidence of ovarian cancer in the ge...
Treatment patterns and prognosis of patients with locally advanced vulvar cancer: a retrospective cohort study of the SEER database and a Chinese multicenter registry
BackgroundVulvar cancer is a rare gynecologic cancer with limited guideline consensus, particularly for locally advanced d...
Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study
Ovarian clear cell carcinoma (OCCC) is a distinct histologic subtype of epithelial ovarian cancer, comprising approximatel...
Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3001)
Endometrial cancer (EC) is the most common gynecological cancer worldwide [1]. In South Korea, EC surpassed other gynecolo...
Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC)
Ovarian cancer (OC) is one of the most lethal gynecologic malignancies, with a 5-year survival rate of merely 50 % [1]. Du...
Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis
Low-grade serous ovarian carcinoma (LGSOC) is a rare histologic subtype of ovarian cancer, which accounts for less than 10...
Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches
Following initial treatment for gynaecological cancer, patients transition to follow-up care [1,2]. This care has two main...
Load More
format_indent_increase